Darbepoetin alfa

Darbepoetin alfa

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN US FDA: Darbepoetin_alfa
ATC code	B03XA02 (WHO)
Identifiers
CAS Number	11096-26-7
DrugBank	BTD00032
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C815H1317N233O241S5
Molar mass	18396.1 g/mol

WikiDoc Resources for Darbepoetin alfa
Articles
Most recent articles on Darbepoetin alfa Most cited articles on Darbepoetin alfa Review articles on Darbepoetin alfa Articles on Darbepoetin alfa in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Darbepoetin alfa Images of Darbepoetin alfa Photos of Darbepoetin alfa Podcasts & MP3s on Darbepoetin alfa Videos on Darbepoetin alfa
Evidence Based Medicine
Cochrane Collaboration on Darbepoetin alfa Bandolier on Darbepoetin alfa TRIP on Darbepoetin alfa
Clinical Trials
Ongoing Trials on Darbepoetin alfa at Clinical Trials.gov Trial results on Darbepoetin alfa Clinical Trials on Darbepoetin alfa at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Darbepoetin alfa NICE Guidance on Darbepoetin alfa NHS PRODIGY Guidance FDA on Darbepoetin alfa CDC on Darbepoetin alfa
Books
Books on Darbepoetin alfa
News
Darbepoetin alfa in the news Be alerted to news on Darbepoetin alfa News trends on Darbepoetin alfa
Commentary
Blogs on Darbepoetin alfa
Definitions
Definitions of Darbepoetin alfa
Patient Resources / Community
Patient resources on Darbepoetin alfa Discussion groups on Darbepoetin alfa Patient Handouts on Darbepoetin alfa Directions to Hospitals Treating Darbepoetin alfa Risk calculators and risk factors for Darbepoetin alfa
Healthcare Provider Resources
Symptoms of Darbepoetin alfa Causes & Risk Factors for Darbepoetin alfa Diagnostic studies for Darbepoetin alfa Treatment of Darbepoetin alfa
Continuing Medical Education (CME)
CME Programs on Darbepoetin alfa
International
Darbepoetin alfa en Espanol Darbepoetin alfa en Francais
Business
Darbepoetin alfa in the Marketplace Patents on Darbepoetin alfa
Experimental / Informatics
List of terms related to Darbepoetin alfa

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Darbepoetin alfa (rINN) (Template:PronEng) is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy. Darbepoetin is marketed by Amgen under the trade name Aranesp.

It was approved in September 2001 by the Food and Drug Administration for treatment of anemia in patients with chronic renal failure by intravenous or subcutaneous injection. In June 2001, it had been approved by the European Medicines Agency for this indication as well as the treatment of anemia in cancer patients undergoing chemotherapy.

It is produced by recombinant DNA technology in modified Chinese hamster ovary cells. It differs from endogenous erythropoietin by containing two more N-linked oligosaccharide chains. It is an erythropoiesis stimulating 165-amino acid protein.

Like EPO its use increases the risk of cardiovascular problems, including cardiac arrest, seizures, arrhythmia or strokes, hypertension and hypertensive encephalopathy, congestive heart failure, vascular thrombosis or ischemia, myocardial infarction and edema. A recent study has extended these findings to treatment of patients exhibiting cancer-related anemia (distinct from anemia resulting from chemotherapy). Pre-existing hypertension contra-indicates the use of darbepoetin as does existing a hematologic disease. Adverse reactions can include hypotension, fever, chest pains, nausea and myalgia.

Also like EPO it has the potential to be abused by athletes seeking an advantage. Its use during the 2002 Winter Olympic Games to improve performance led to the disqualification of cross-country skiers Larisa Lazutina and Olga Danilova of Russia and Johann Mühlegg of Spain from their final races.

Safety advisories in anemic cancer patients

Amgen sent a "dear doctor" letter in January, 2007, that highlighted results from a recent anemia of cancer trial, and warned doctors to consider use in that off-label indication with caution.

Amgen advised the United States FDA as to the results of the DAHANCA 10 clinical trial. The DAHANCA 10 data monitoring committee found that 3-year loco-regional control in subjects treated with Aranesp was significantly worse than for those not receiving Aranesp (p=0.01).

In response to these advisories, the FDA released a Public Health Advisory on March 9, 2007, and a clinical Alert for doctors on February 16, 2007, about the use of erythropoeisis-stimulating agents such as epogen and darbepoeitin. The advisory recommended caution in using these agents in cancer patients receiving chemotherapy or off chemotherapy, and indicated a lack of clinical evidence to support improvements in quality of life or transfusion requirements in these settings.

In addition, on March 9, 2007, drug manufacturers agreed to new "black box" warnings about the safety of these drugs. On November 8, 2007, additional "black box" warnings were included on the aranesp label, at the request of the FDA.

On March 22, 2007, a congressional inquiry into the safety of erythropoeitic growth factors was reported in the news media. Manufacturers were asked to suspend drug rebate programs for physicians and to also suspend marketing the drugs to patients.

Business considerations for drug manufacturers

Epogen and Darbepoeitin alfa had more than $6 billion in combined sales in 2006. Procrit sales were about $3.2 billion in 2006.